Evidence map›Paper›PMID 34329392›Full record

ArticleBlood2022

The secreted tyrosine kinase VLK is essential for normal platelet activation and thrombus formation.

Leila Revollo, Glenn Merrill-Skoloff, Karen De Ceunynck, James R Dilks, Shihui Guo, Mattia R Bordoli, Christian G Peters, Leila Noetzli, Andreia Ionescu, Vicki Rosen and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Leila RevolloDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA.
Glenn Merrill-SkoloffDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Karen De CeunynckDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
James R DilksDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Shihui GuoDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-0542-1221
Mattia R BordoliDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA.
Christian G PetersDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Leila NoetzliDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Andreia IonescuDepartment of Biology, Northeastern University, Boston, MA.
Vicki RosenDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA.
Joseph E ItalianoDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Malcolm WhitmanDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA.
Robert FlaumenhaftDivision of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Beth Israel Deaconess Medical Center · USHarvard University · USBrigham and Women's Hospital · USNortheastern University · US

Funding

PROGRAM IN BLOOD COAGULATION AND VASCULAR BIOLOGYT32HL007917 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Robert C Flaumenhaft · 1999 to 2026
$11.1M
Cytoskeletal Mechanisms of Platelet FormationR01HL068130 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ITALIANO, JOSEPH E · 2001 to 2021
$8.1M
Thiol Isomerases in Hemostasis and ThrombosisR35HL135775 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLAUMENHAFT, ROBERT C · 2017 to 2023
$5.5M
Targeting the Endothelium in SepsisR01HL125275 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLAUMENHAFT, ROBERT C, PARIKH, SAMIR M · 2014 to 2018
$4.2M
Vascular Thiol Isomerases in ThrombosisR01HL136394 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ITALIANO, JOSEPH E, ZWICKER, JEFFREY · 2017 to 2020
$3.3M
Role of the First Secreted Tyrosine Kinase in Bone Development, Homeostasis, and RepairR01AR066717 · NIAMS · HARVARD MEDICAL SCHOOL · PI ROSEN, VICKI, WHITMAN, MALCOLM R. · 2015 to 2019
$3.2M
The first secreted Tyrosine kinaseR01GM115417 · NIGMS · HARVARD MEDICAL SCHOOL · PI WHITMAN, MALCOLM R. · 2015 to 2018
$1.5M
Role of a Novel Secreted Protein Tyrosine Kinase in DevelopmentR21DE024312 · NIDCR · HARVARD MEDICAL SCHOOL · PI WHITMAN, MALCOLM R. · 2014 to 2015
$618k
NHLBI NIH HHS R01 HL068130NHLBI NIH HHS R01 HL125275NHLBI NIH HHS R01 HL136394NHLBI NIH HHS R35 HL135775NHLBI NIH HHS T32 HL007917NIAMS NIH HHS R01 AR066717NIDCR NIH HHS R21 DE024312NIGMS NIH HHS R01 GM115417
6 · The paper itself

Abstract

Tyrosine phosphorylation of extracellular proteins is observed in cell cultures and in vivo, but little is known about the functional roles of tyrosine phosphorylation of extracellular proteins. Vertebrate lonesome kinase (VLK) is a broadly expressed secretory pathway tyrosine kinase present in platelet α-granules. It is released from platelets upon activation and phosphorylates substrates extracellularly. Its role in platelet function, however, has not been previously studied. In human platelets, we identified phosphorylated tyrosines mapped to luminal or extracellular domains of transmembrane and secreted proteins implicated in the regulation of platelet activation. To determine the role of VLK in extracellular tyrosine phosphorylation and platelet function, we generated mice with a megakaryocyte/platelet-specific deficiency of VLK. Platelets from these mice are normal in abundance and morphology but have significant changes in function both in vitro and in vivo. Resting and thrombin-stimulated VLK-deficient platelets exhibit a significant decrease in several tyrosine phosphobands. Results of functional testing of VLK-deficient platelets show decreased protease-activated receptor 4-mediated and collagen-mediated platelet aggregation but normal responses to adenosine 5'-diphosphate. Dense granule and α-granule release are reduced in these platelets. Furthermore, VLK-deficient platelets exhibit decreased protease-activated receptor 4-mediated Akt (S473) and Erk1/2 (T202/Y204) phosphorylation, indicating altered proximal signaling. In vivo, mice lacking VLK in megakaryocytes/platelets display strongly reduced platelet accumulation and fibrin formation after laser-induced injury of cremaster arterioles compared with control mice but with normal bleeding times. These studies show that the secretory pathway tyrosine kinase VLK is critical for stimulus-dependent platelet activation and thrombus formation, providing the first evidence that a secreted protein kinase is required for normal platelet function.

Indexed as

Platelet ActivationAnimalsBlood PlateletsGene DeletionHEK293 CellsHumansMice, TransgenicProtein-Tyrosine KinasesThrombosisPKDCC protein, humanProtein-Tyrosine KinasesVlk protein, mouse

Identifiers

PMID34329392
PMCPMC8718620
OpenAlexW3096091135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.